The life science manufacturer Cytiva has been growing its footprint across the globe this year, but its latest move will see it boost its attention toward the technology for making cell therapies.
Cytiva has acquired CEVEC Pharmaceuticals, a German provider of high-performance cell line development and viral vector manufacturing technologies, further strengthening Cytiva's biomanufacturing services.
Cevec Pharmaceuticals GmbH and Rokote Laboratories Finland Ltd have signed an agreement on the use of Cevec’s proprietary CAP Ad Technology for the manufacturing of vaccines in various indications.
CEVEC Pharmaceuticals signed a non-exclusive agreement with Biogen for the use of CEVEC’s proprietary Elevecta technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products. Under the license, CEVEC is eligible for technology access and milestone fees, including clinical development and commercial milestones, as well as royalties on net sales of products.
CEVEC Pharmaceuticals GmbH (CEVEC) signed a license agreement with Biogen Inc. for the use of CEVEC’s ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
Cevec Pharma announced the signing of an option and license agreement with Roche for the use of its newly launched Elevecta technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.